<DOC>
	<DOCNO>NCT01728298</DOCNO>
	<brief_summary>The primary objective trial evaluate dose-response relationship regard change immunological parameter safety SLITone ULTRA house dust mite mix adult subject moderate severe HDM allergic rhinitis .</brief_summary>
	<brief_title>A Dose Response Evaluation SLITone Ultra HDM Mix Immunotherapy</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Aged 18 old Moderate severe persistent HDM allergic rhinitis without asthma Moderate severe HDM allergic rhinitis symptom baseline period Positive skin prick test response ( wheal diameter ≥ 3 mm ) Positive specific IgE ≥ IgE Class 2 , ≥ 0.70 kU/l ) Previous treatment immunotherapy House dust mite immunotherapy Ongoing treatment allergen specific immunotherapy product Reduced lung function Clinical history uncontrolled asthma Inflammatory condition oral cavity severe symptom History anaphylaxis cardiorespiratory symptom History recurrent generalise urticaria A history drug induce facial angioedema hereditary angiooedema Any clinically relevant chronic disease ( ≥3 month duration ) Systemic disease affect immune system Immunosuppressive treatment Currently treat tricyclic antidepressant ; catecholamineMethyltransferase inhibitor mono amine oxidase inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>House Dust Mite</keyword>
	<keyword>allergy</keyword>
	<keyword>rhinitis</keyword>
	<keyword>asthma</keyword>
</DOC>